SAN FRANCISCO, Dec. 8, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced disease stabilization in some multiple myeloma patients treated with milatuzumab.
